Last updated: September 22, 2026
Talazoparib tosylate, marketed by Pfizer as Talzenna, is a targeted PARP inhibitor used in germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer and, with enzalutamide, in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. Global sales have grown from a small oncology launch base to roughly $270 million annually, but the product remains exposed to intense PARP competition, biomarker-testing constraints, and future generic entry risk.
What is the current commercial status of talazoparib tosylate?
Talazoparib is an oral poly ADP-ribose polymerase, or PARP, inhibitor. Its clinical value comes from two related mechanisms: catalytic PARP inhibition and PARP-DNA trapping. The drug is administered as talazoparib tosylate capsules under the Talzenna brand.
| Item |
Status |
| Active ingredient |
Talazoparib |
| Commercial salt |
Talazoparib tosylate |
| Brand |
Talzenna |
| Sponsor |
Pfizer |
| Original development rights |
BioMarin; later acquired through Medivation |
| FDA approval |
October 2018 |
| Initial indication |
Germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer |
| Expanded indication |
HRR gene-mutated metastatic castration-resistant prostate cancer with enzalutamide |
| Primary competitors |
Lynparza, Rubraca, Zejula, and other PARP-based regimens |
| Delivery |
Oral capsule, once daily |
| Main commercial markets |
United States, Europe, Japan, and other international markets |
The initial breast-cancer approval was based principally on the EMBRACA trial, which showed a progression-free-survival advantage over physician-choice chemotherapy in patients with germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.[1] The prostate-cancer expansion was approved in June 2023 for talazoparib in combination with enzalutamide in adults with HRR gene-mutated metastatic castration-resistant prostate cancer.[2]
How has Talzenna revenue changed over time?
Pfizer’s reported Talzenna revenue increased rapidly after launch, supported by wider testing for germline BRCA mutations and the 2023 prostate-cancer combination approval.
| Fiscal year |
Reported global revenue |
| 2019 |
Approximately $77 million |
| 2020 |
Approximately $134 million |
| 2021 |
Approximately $180 million |
| 2022 |
Approximately $226 million |
| 2023 |
Approximately $270 million |
Source: Pfizer annual reports and product-revenue disclosures.[3-7]
The trajectory reflects three commercial phases:
-
Launch phase, 2019-2020. Adoption was limited to a biomarker-defined breast-cancer population. Reimbursement depended on documented germline BRCA testing and prior treatment history.
-
Breast-cancer expansion, 2021-2022. Sales rose as oncology practices became more familiar with PARP inhibitors and genetic testing became more integrated into metastatic breast-cancer treatment.
-
Prostate-cancer expansion, 2023 onward. The combination with enzalutamide materially expanded the addressable population. The commercial effect is constrained by competition from olaparib combinations and the high prevalence of androgen-receptor pathway treatment in prostate cancer.
Pfizer does not generally disclose Talzenna profitability, gross margin, or indication-specific revenue. Product-level sales therefore provide the clearest public measure of commercial performance.
What is driving the talazoparib market?
Which patients are eligible for treatment?
Talazoparib is concentrated in molecularly selected oncology populations. The principal eligibility drivers are:
- Germline BRCA1 or BRCA2 mutation in HER2-negative advanced breast cancer.
- HRR gene alterations in metastatic castration-resistant prostate cancer.
- Prior systemic therapy and disease stage.
- Local treatment guidelines and payer requirements.
- Availability and reimbursement of genetic testing.
The biomarker requirement improves response enrichment but limits volume. Talazoparib does not compete for the full breast-cancer or prostate-cancer population. Its revenue depends on the number of patients tested, the proportion carrying qualifying alterations, and treatment sequencing after prior therapies.
How important is the enzalutamide combination?
The prostate-cancer combination is the main growth catalyst for Talzenna. Enzalutamide gives Pfizer access to a large established prostate-cancer franchise, while talazoparib adds a biomarker-selected layer.
The combination has two commercial advantages:
- Pfizer can promote talazoparib alongside an established androgen-receptor inhibitor.
- The regimen can be positioned in patients with selected HRR alterations who may have limited targeted options.
The principal limitation is overlap with Lynparza plus abiraterone, which addresses a similar prostate-cancer treatment segment. Physicians may choose between regimens based on gene alteration, prior therapy, toxicity, treatment guidelines, payer rules, and familiarity with the backbone drug.
How does talazoparib compare with competing PARP inhibitors?
| Drug |
Company |
Main oncology position |
Key commercial issue |
| Talazoparib |
Pfizer |
Germline BRCA breast cancer; HRR-mutated mCRPC with enzalutamide |
Smaller installed base than olaparib; prostate-combination growth opportunity |
| Olaparib |
AstraZeneca/Merck |
Breast, ovarian, pancreatic, and prostate cancer |
Broadest indication base and strong physician familiarity |
| Rucaparib |
Clovis Pharma; later CStone-related assets |
Ovarian and prostate cancer history |
Commercial contraction after regulatory and competitive setbacks |
| Niraparib |
GSK |
Ovarian cancer and related maintenance settings |
Strong ovarian-cancer position but narrower relevance in breast and prostate |
| Veliparib |
AbbVie development program |
No comparable marketed position |
Development and commercial status differ by jurisdiction |
Olaparib remains the strongest direct competitive benchmark because it has broader tumor coverage and established prostate-cancer use. Talazoparib’s differentiation is based on potent PARP trapping, the EMBRACA breast-cancer data set, and the enzalutamide combination rather than broad label coverage.
What FDA regulatory status does talazoparib have?
The FDA approved Talzenna in October 2018 for adults with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer.[8] The label requires an FDA-approved companion diagnostic for identifying patients with germline BRCA mutations.
In June 2023, the FDA approved Talzenna with enzalutamide for adults with HRR gene-mutated metastatic castration-resistant prostate cancer.[2] The approval expanded Pfizer’s target population but made treatment selection more dependent on genomic testing.
Talazoparib has not been approved as a biosimilar-type product because it is a chemically synthesized small molecule. Future competition will come through abbreviated new drug applications, or ANDAs, rather than the biosimilar pathway.
What patents protect talazoparib and when could generic entry occur?
Talazoparib protection is based on a combination of composition-of-matter, pharmaceutical-composition, and regulatory exclusivity rights. Public patent records associate the product with Pfizer and predecessor development entities, including patents covering substituted heterocyclic compounds and talazoparib formulations.
The central U.S. patent estate has historically included patents with expirations extending into the late 2020s or around 2030, depending on the specific claim, patent-term adjustment, patent-term extension, and product listing. The effective generic-entry date therefore depends on:
- The specific Orange Book-listed patent claims.
- Any patent-term extension.
- Pediatric exclusivity.
- ANDA filing dates.
- Paragraph IV certifications.
- Patent litigation and settlement terms.
- Whether a generic applicant challenges only the active ingredient or also formulation and method claims.
What is the Orange Book status?
The FDA Orange Book is the operative source for listed patents and exclusivity. Talzenna’s listing has included patents directed to the active compound and related pharmaceutical protection. Orange Book protection is generally more relevant to generic entry than the broader global patent portfolio because an ANDA applicant must address listed U.S. patents.
Talazoparib has no biologic biosimilar barrier. Once relevant U.S. patents and exclusivities expire or are successfully challenged, an ANDA applicant could seek approval for the same active ingredient and dosage form.
Are Paragraph IV challenges publicly material?
No major, widely reported Paragraph IV litigation wave had materially altered Talzenna’s commercial outlook through mid-2024. The principal near-term risk remained later-cycle ANDA activity rather than an established generic launch.
A Paragraph IV filing could target:
- The core compound patent.
- The tosylate salt or pharmaceutical composition.
- Capsule strength and formulation claims.
- Use in BRCA-mutated breast cancer.
- Use in HRR-mutated prostate cancer.
Formulation and method-of-use patents can delay entry, but they usually provide narrower protection than a valid composition-of-matter patent. The commercial impact of a challenge would depend on whether the generic applicant receives approval for all listed strengths and whether Pfizer settles before trial.
What manufacturing and intellectual-property barriers affect talazoparib?
Talazoparib is a small molecule, so manufacturing barriers are lower than for monoclonal antibodies or cell therapies. A generic manufacturer must still demonstrate:
- Pharmaceutical equivalence.
- Bioequivalence.
- Control of the active pharmaceutical ingredient.
- Reproducible impurity and stereochemical profiles.
- Stable capsule formulation.
- Compliance with current good manufacturing practices.
The commercial barrier is more likely to be patent timing and market access than chemical synthesis. Pfizer’s brand position, established oncology relationships, and combination use with enzalutamide create additional commercial friction for a new entrant, but these factors would not prevent substitution after generic approval.
What litigation and settlement risks affect Talzenna?
The important legal risks are conventional small-molecule patent risks:
- A Paragraph IV challenge could accelerate entry.
- A successful Pfizer infringement action could delay approval or launch.
- A settlement could establish a licensed or agreed entry date before patent expiry.
- A skinny-label generic could avoid some method-of-use claims while competing in unprotected indications.
- At-risk launch could expose the generic applicant to damages if Pfizer prevails.
No major public settlement had established an earlier Talzenna generic entry date through mid-2024. The absence of a reported settlement does not eliminate future litigation risk; it means no widely disclosed agreement had changed the public launch framework at that time.
What is the long-term financial outlook for talazoparib?
Talzenna should continue growing in the near term if the enzalutamide combination expands testing and treatment in HRR-mutated prostate cancer. Growth is likely to moderate as:
- Olaparib-based combinations compete for the same prostate-cancer patients.
- PARP use becomes concentrated in earlier treatment lines.
- Payers impose genomic-testing and utilization controls.
- The breast-cancer market reaches a mature penetration level.
- Generic applicants approach the earliest viable entry date.
A reasonable commercial framework is:
| Period |
Expected market dynamic |
| 2024-2026 |
Combination-driven growth, led by prostate cancer |
| 2026-2029 |
Slower growth as competition and sequencing pressure increase |
| Late 2020s onward |
Patent and ANDA risk becomes the central value driver |
| Post-entry |
Rapid price erosion typical of oral oncology generics, with magnitude dependent on the number of entrants |
Talazoparib is unlikely to become a multibillion-dollar product without additional indications or a major shift in treatment sequencing. Its more probable profile is a durable specialty-oncology product with peak sales in the several-hundred-million-dollar range, followed by erosion when generic competition becomes legally and commercially viable.
How strong is the talazoparib patent estate?
The estate is commercially meaningful but not exceptionally broad compared with products protected by multiple indications, formulations, and biologic manufacturing barriers.
| Strength factor |
Assessment |
| Active-ingredient protection |
Strongest protection if valid and unexpired |
| Biomarker method claims |
Valuable but narrower and vulnerable to label design |
| Formulation protection |
Useful secondary protection |
| Manufacturing complexity |
Moderate for a small molecule |
| Regulatory exclusivity |
Limited relative to biologics |
| Biosimilar barrier |
None |
| Competitive differentiation |
Moderate; strongest in selected breast and prostate populations |
| Generic exposure |
Material in the late 2020s or around the end of the core patent term |
Key Takeaways
- Talazoparib tosylate is Pfizer’s Talzenna, an oral PARP inhibitor for biomarker-selected breast and prostate cancers.
- Revenue increased from about $77 million in 2019 to approximately $270 million in 2023.
- The 2023 approval with enzalutamide is the product’s main commercial growth driver.
- Olaparib is the strongest direct competitor because of its broader indications and established prostate-cancer position.
- The product is protected by small-molecule patents rather than biologic exclusivity.
- Generic risk becomes more important as core U.S. patent protection approaches the late 2020s or around 2030.
- Talzenna’s long-term value depends on prostate-cancer uptake, genomic testing, competitive sequencing, and the timing of Paragraph IV activity.
- The likely financial profile is continued near-term growth followed by mature specialty-drug sales and eventual oral-generic price erosion.
FAQs
What is talazoparib tosylate used for?
It is used for germline BRCA-mutated, HER2-negative advanced or metastatic breast cancer and, with enzalutamide, for HRR gene-mutated metastatic castration-resistant prostate cancer.
Who manufactures Talzenna?
Pfizer manufactures and commercializes Talzenna globally. The product originated from development programs associated with BioMarin and Medivation before Pfizer acquired Medivation.
Is talazoparib the same as olaparib?
No. Both are PARP inhibitors, but they are different active ingredients with different clinical labels, patent estates, dosing, safety profiles, and competitive positions.
Will there be a generic version of Talzenna?
Generic talazoparib is possible after relevant patents and exclusivities expire or are successfully challenged. Generic timing will depend on ANDA filings, Paragraph IV certifications, litigation, and any settlement agreements.
Does talazoparib have biosimilar competition?
No. Talazoparib is a chemically synthesized small molecule. Any future copy product would generally proceed through the generic-drug pathway rather than the biosimilar pathway.
References
-
Litton, J. K., Rugo, H. S., Ettl, J., et al. (2018). Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. New England Journal of Medicine, 379(8), 753-763.
-
U.S. Food and Drug Administration. (2023). FDA approves talazoparib with enzalutamide for metastatic castration-resistant prostate cancer. FDA.
-
Pfizer Inc. (2020). 2020 annual report. Pfizer.
-
Pfizer Inc. (2021). 2021 annual report. Pfizer.
-
Pfizer Inc. (2022). 2022 annual report. Pfizer.
-
Pfizer Inc. (2023). 2023 annual report. Pfizer.
-
Pfizer Inc. (2024). Fourth-quarter and full-year 2023 financial results. Pfizer.
-
U.S. Food and Drug Administration. (2018). Talzenna prescribing information. FDA.
